We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Population Deep Sequencing Identifies Pockets of Multi-Drug Resistant and Virulent Pathogen

3D representation of a DNA double helix spiraling into the distance.
Credit: Pixabay.

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Population Deep Sequencing Identifies Pockets of Multi-Drug Resistant and Virulent Pathogen"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Unparalleled insights into the secret life of Streptococcus pneumoniae, the bacterium responsible for hundreds of thousands of infant deaths each year, have been revealed by new research from the Wellcome Sanger Institute, the University of Oxford, the Shoklo Malaria Research Unit and Imperial College London.


The study, published today (10 October) in Nature Microbiology, details the genetic diversity of the pathogen within individual infants, including hidden multidrug-resistant and virulent strains. The findings suggest that the detection of such resistant variants is only possible using a population deep sequencing (PDS) approach and that their presence may be due to individuals being treated with antibiotics.


The research highlights the potential for PDS to improve our understanding of pathogens like S. pneumoniae and to inform treatment strategies when antimicrobial resistance is a concern.


Streptococcus pneumoniae, also known as the pneumococcus, is a bacterial pathogen that causes diseases ranging from ear infections through to pneumonia, septicaemia and meningitis. It is responsible for around nine million global infections annually, with elderly adults and children particularly susceptible. More than 300,000 children die from pneumococcal infection each year, mainly in low- and middle-income countries (LMICs)1.


Not all individuals colonised by S. pneumoniae will become ill. The bacterium is carried without symptoms by up to 60 per cent of children2 and by a smaller percentage of adults. Children are generally colonised by common strains, and this allows our immune systems to recognise and guard against them. As adults, we tend to be colonised by rarer strains that we may not have encountered before.


In this new study, researchers at the Wellcome Sanger Institute, the University of Oxford and Imperial College London set out to document the diversity of S. pneumoniae in children and adults.


Almost 4,000 samples, collected from infants and mothers over a two-year period3, were whole genome sequenced to test whether the full diversity of S. pneumoniae lineages present could be mapped. Similarly to previous research, common serotypes such as 19F and 23F were much more likely to be found in infants4. Serotype 3, which is responsible for disease in adults, was the only one to be found more frequently in mothers.


Importantly, the enhanced sensitivity of this genomics-based method compared to standard tests showed that rarer serotypes linked to disease were present in infants, but at low levels.


Dr Gerry Tonkin-Hill, a first author of the study from the Wellcome Sanger Institute, said: “Most bacterial studies only look at one genome per person, but this means that the full diversity of the bacteria that we’re colonised by goes unrecorded. We wanted to see what we were missing by analysing many genomes taken from the same person simultaneously. The results of this study confirm that whole genome sequencing of populations of bacterial genomes is a highly accurate and effective way to do this, as shown by the detection of low numbers of disease-linked serotypes in infants.”


Genomic sequence data were also compared to antibiotic treatments received by individuals who became ill while taking part in the study. Analysis indicated that infants were at higher risk of being colonised by multidrug resistant lineages following treatment.


In contrast, common lineages that are susceptible to treatment were found to outcompete these multidrug resistant lineages in infants who hadn’t received antibiotic treatment.


Dr Clare Ling, a first author of the study from Shoklo Malaria Research Unit, Thailand, said: “Humans, particularly children, often host numerous pneumococcal strains simultaneously, which are competing with each other and with strains from other species. In a way it is good news that strains that we can treat with antibiotics are more dominant than resistant strains under normal circumstances, but the fact that treatment gives multi-drug resistant strains an advantage is concerning.”


Similarly to other pathogens that regularly infect humans, there is a growing threat from antimicrobial resistant strains of S. pneumoniae that are not susceptible to commonly-used medicines. It is thought that overuse of antibiotics contributes to resistance, yet these drugs save lives and remain our best defence against infectious bacteria. One way to improve our use of antibiotics is through precision medicine, where the strain causing an infection is identified so that the most appropriate drugs can be used.


Professor Stephen Bentley, a senior author of the study from the Wellcome Sanger Institute, said: “The high resolution of this study allows us to trace the course of S. pneumoniae infection over time, finally giving us the data we need to settle questions such as how drug-susceptible and drug-resistant bacteria compete against one another. This approach shows us how, with sufficient resourcing and expertise, genomic surveillance can provide the information we need to understand the strains causing infections, and which treatments are most likely to succeed.”


Reference: Tonkin-Hill G, Ling C, Chaguza C, et al. Pneumococcal within-host diversity during colonization, transmission and treatment. Nat Microbiol. Published online October 10, 2022:1-14. doi:10.1038/s41564-022-01238-1



This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement